Elon Musk’s brain-computer interface (BCI) startup, Neuralink, reportedly received approval from the United States Food and Drug Administration (FDA) to conduct some form of “in-human” trials for its surgically implanted brain device.
Congratulations Neuralink team! https://t.co/AWZGf33UDr
It’s unclear at this time what kind of trials the Neuralink tweet is referring to — the only other information mentioned was that the company isn’t accepting applicants yet.
Neuralink was denied the FDA’s approval for human trials in early 2022 over several concerns related to safety, which, at the time, the company was reportedly working to resolve.
The FDA’s apparent U-turn would indicate that such concerns have been worked out, and the company should then be free to conduct limited testing of its surgically implanted BCI device.
In describing the function of the BCI, Elon Musk has stated it would help with certain medical and mobility issues. BCIs are developed for the treatment of numerous conditions, such as epilepsy. They also provide quality-of-life services for disabled persons, such as the ability to direct a mouse cursor via eye movement or thought.
Musk has also said the device would be developed for use by the general public as a general-purpose BCI, which allows humans to interface with machines via thought and protect us from being replaced by machines.
Until now, Neuralink has only been allowed to conduct testing on laboratory animals such as monkeys and pigs. The company recently faced a federal probe over alleged animal mistreatment; however, Neuralink denied any wrongdoing, and the investigation appears to have ended quietly. A separate investigation over the alleged transportation of contaminated devices remainsRead more on cointelegraph.com